In a 28-year period, 39 (7%) patients with chronic myelomonocytic leukemia (CMML) (median age 66 years, 64% male) underwent a splenectomy at our institution. Primary indications for splenectomy were refractory thrombocytopenia (36%), progressive spleen related symptoms (33%), emergent splenectomy for splenic rupture (21%), refractory anemia (8%), and prior to allogeneic stem cell transplant (3%). Eleven (28%) patients had anemia at the time of splenectomy, of which 3 (27%) were autoimmune. The median time to splenectomy from CMML diagnosis was 6 months (0-40); perioperative morbidity and mortality rates were 43% and 13%, while the median postsplenectomy survival was 25 months (11-38). Durable remission in spleen related symptoms, thrombocytopenia, complications from splenic rupture, and anemia were achieved in 85%, 50%, 62%, and 21% of patients, respectively. Perioperative morbidity (n = 30) included infections/sepsis in 6 (20%), intraabdominal bleeding in 4 (13%), venous thromboembolism (VTE) in 3 (10%), and acute lung injury in 2 (7%) patients. The median duration of hospital stay was 6 days (1-25), with 5 deaths occurring secondary to respiratory failure (n = 2), multiorgan dysfunction (n = 2) and hemorrhagic shock (n = 1). There was no difference in overall survival between CMML patients that underwent splenectomy, in comparison to those that did not. Unlike in myelofibrosis, portal hypertension was not an indication for splenectomy and no patients developed post-splenectomy thrombocytosis. In conclusion, apart from being a lifesaving emergent modality in the event of splenic rupture, splenectomy has an important palliative role in patients with CMML, with significant and durable improvements in spleen related symptoms and refractory cytopenias. Extramedullary hematopoiesis (EMH) resulting in splenomegaly, hepatomegaly, and lymphadenopathy can be seen in patients with CMML, with a recent study (n = 452) demonstrating palpable hepatosplenomegaly in 27% of patients at diagnosis; 14% with isolated splenomegaly and 3% with isolated hepatomegaly. 4 The presence of palpable hepatosplenomegaly was associated with a "proliferative" CMML subtype and was found to be independently associated with an inferior overall survival (OS).
/L for the latter. 3 Extramedullary hematopoiesis (EMH) resulting in splenomegaly, hepatomegaly, and lymphadenopathy can be seen in patients with CMML, with a recent study (n = 452) demonstrating palpable hepatosplenomegaly in 27% of patients at diagnosis; 14% with isolated splenomegaly and 3% with isolated hepatomegaly. 4 The presence of palpable hepatosplenomegaly was associated with a "proliferative" CMML subtype and was found to be independently associated with an inferior overall survival (OS). 4 Splenectomy has been an important component of palliative therapy in patients with myelofibrosis, a related myeloid neoplasm with frequent EMH. In a large Mayo Clinic study (n = 223), indications for splenectomy included red blood cell (RBC) transfusion dependent anemia (45%), drug-refractory symptomatic splenomegaly (39%), portal hypertension and related sequela (11%) and refractory thrombocytopenia (5%). 5 The operative mortality was 9%, while the operative morbidity was 31%; median postsplenectomy survival was 27 months (0-155 months). The salutatory effects of splenectomy included, improvement in constitutional spleen related symptoms in 67%, alleviation of RBC transfusion need in 23%, improvement in portal hypertension in 50%; with absolutely no sustained platelet count responses. 5 Surgical complications in this series included postoperative bleeding in 15%, infection in 9% and thrombosis in 7%; with death resulting from the aforementioned complications in 4.5%, 2.7%, and 1.3%, of patients respectively. 5 In a recent analysis on 120 myelofibrosis patients that underwent a splenectomy, older age at surgery, RBC transfusion need and postoperative leukocytosis with ≥5% circulating blasts were associated with a shortened postsplenectomy survival (median OS <6 months, if all three risk factors were present). 6 Indications and outcomes of splenectomy are not well described in patients with CMML. In a prior series of 12 Mayo Clinic patients with CMML, splenectomy was carried out largely for refractory thrombocytopenia (58%) and mechanical spleen related symptoms (25%). 7 The postoperative mortality was 25%, while 33% suffered significant morbidity. Platelet responses were documented in 36% of patient, while EMH was seen in all spleen specimens on histology. 7 Given the paucity of data in CMML, we carried out this study in a larger, more informative group of molecularly annotated CMML patients, so as to define (1) indications, (2) clinical outcomes (morbidity and mortality), and (3) survival after splenectomy.
| MATERIALS AND METHODS
Five hundred and fifty five patients with CMML were included in the study. After obtaining Mayo Clinic IRB approval, a detailed retrospective chart review was performed to identify patients with CMML that had undergone a splenectomy. All study patients had bone marrow (BM) biopsies and cytogenetic studies performed at diagnosis. The diagnosis of CMML, including subclassification into CMML-0,1, and 2, and into "proliferative" and "dysplastic" variants and leukemic blast transformation (LT) were according to the 2016, WHO criteria. TET2, DNMT3A, IDH1,   IDH2, ASXL1, EZH2, SUZ12, SRSF2, SF3B1, ZRSR2, U2AF1, PTPN11,   Tp53, SH2B3, RUNX1, CBL, NRAS, KRAS, JAK2, CSF3R, FLT3, KIT, CALR,   MPL, NPM1, CEBPA, IKZF, ETNK1 , and SETBP1, by previously described methods. 11, 12 Relevant data collected in patients that underwent a splenectomy included indications for splenectomy, CMML disease status and risk stratification, complete blood counts prior to and after splenectomy, postoperative morbidity, mortality and survival and disease and symptom related responses. The spleen histopathology was reviewed in detail by an independent hematopathologist and pathological findings were summated and correlated with presenting clinical findings.
Spleen related symptoms were classified as constitutional if they were associated with left hypochondrial/upper abdominal fullness, early satiety, anorexia, cachexia, fevers, chills and drenching night sweats (sustained presence of ≥1 symptom), or mechanical, if they were associated with spleen related pain and/or obstructive symptoms involving the adjacent gastrointestinal or genitourinary organ systems.
Responses to peripheral blood cytopenias were graded based on the 2006 International Working Group (IWG) MDS response criteria. 13 Based on these criteria, an erythroid response was defined by a sustained hemoglobin (HB) increase of 1.5 g/dL, over the presplenectomy HB values (baseline <11 g/dL), along with a relevant reduction in the number of units of RBC by an absolute number of at least 4 RBC transfusions in 8 weeks (compared with the pretreatment transfusion number in the previous 8 weeks). 13 Platelet responses were documented for an absolute increase of ≥30 × 10(9)/L for patients with a presplenectomy platelet count >20 × 10(9)/L, or to >20 × 10(9)/L, by a relative value of 100%, if the presplenectomy platelet counts were < 20 × 10(9)/L. 13 (9) 3 (13) 27 (9) .53
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(Continues) splenectomy procedure was emergent in 9 (23%) patients (including all 8 patients with splenic rupture) and was performed as an elective procedure in the remainder (77%). In 29 assessable patients where operative details were available, the splenectomy was carried out as an open procedure in 21 (72%) and as a laparoscopic procedure in 8 (28%); with the extent of splenomegaly largely determining the preferred surgical route. Intraoperatively, an accessory spleen was identified and removed in 3 (10%) of 30 assessable cases.
| Indications and outcomes of splenectomy in CMML
The most common indications for splenectomy were refractory thrombocytopenia (n = 14, 36%), followed by progressive spleen related symptoms (n = 13, 33%); of which, 10 (77%) patients had largely mechanical symptoms from massive splenomegaly, while the remaining 3 (23%) had predominant spleen related constitutional symptoms ( Table 2) 
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The bold values represent P values that are statistically significant; P < .05. Abbreviation: MCV, Mean corpuscular volume; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; WBC, white blood cell count; PB, peripheral blood; BM, bone marrow; WHO, World Health Organization; CI, Confidence interval. 
| Postsplenectomy morbidity and mortality
The median time to splenectomy from CMML diagnosis in the cohort was 6 months (range, 0-40 months), with the median times to splenectomy for spleen related symptoms, splenic rupture, and refractory thrombocytopenia being 9, 32, and 1 month, respectively. Surgical morbidity and mortality (within 3 months of splenectomy) rates were 43%
and 13%, respectively, with a median postsplenectomy survival of 25 months (range, 11-38 months). The median intraoperative blood loss was estimated at 275 mL (range, 100-3000 mL); while the median hospital stay was 6 days (range, 1-25 days) (Supporting Information Table 1 ). Four patients were managed in the intensive care unit for perioperative complications. VTE prophylaxis was administered in 11 (65%) of 17 assessable patients and included unfractionated heparin in 64%, low molecular weight heparin in 18%, warfarin in 9% and an IVC filter in 9% (ongoing contraindications to anticoagulation). Perioperative complications were accurately assessable in 30 patients and included infections/sepsis in 6 (20%), intraabdominal bleeding in 4 (13%), VTE in 3 (10%), and acute lung injury in 2 (7%) patients, respectively. There were no cases of postsplenectomy thrombocytosis seen and a compensatory postsplenectomy hepatomegaly was encountered in 19% of patients. Immunization status was accurately assessable in 16 patient and vaccine coverage for streptococcus pneumoniae, neisseria meningitidis and haemophilus influenza B were 100%, 81%, and 63%, respectively. Notably, until last follow up, there were no documented cases of pneumococcal or meningococcal infections/sepsis in the entire cohort.
| Histopathological review
On pathological review of splenectomy specimens, the median weight of resected spleens was 1127 g (range, 80-3995 g). Sections of spleen tissue from 22 (56%) patients were available for an independent review. The most common histopathologic finding was the presence of EMH, as evident on hematoxylin and eosin stained sections in 19 (86%) of 22 cases; with variability in the extent of involvement ranging from rare scattered megakaryocytes to overt trilineage hematopoiesis with red pulp expansion ( Figure 1A ). Ten (45%) specimens demonstrated increased numbers of foamy histiocytes within the expanded red pulp regions. In 4 (40%) of these specimens, the foamy histiocytes were abundant, including in all three patients with suspected immune mediated thrombocytopenia (ITP) ( Figure 10B ). Interestingly all 4 (100%) patients with abundant foamy histiocytes had refractory thrombocytopenia, and endured a sustained IWG platelet response after splenectomy. An infiltrate of myeloid and monocytic cells was evident within the red pulp in 11 specimens (50%) 
| Survival analysis
The median follow up for the CMML splenectomy cohort was 166 months, and at last follow up, 33 (85%) deaths and 8 (21%) leukemic transformations were documented. The median OS for CMML patients that underwent a splenectomy was 27 months and was not statistically different from CMML patients that did not undergo a splenectomy (P = 0.65) (Figure 2A ). There was also no difference in LFS, with the median LFS not being reached in both groups ( Figure 2B ).
Given the smaller number of patients, an effective postsplenectomy prognostic risk factor analysis could not be performed.
| DISCUSSION
Splenomegaly is a common manifestation in patients with CMML (~30% with palpable splenomegaly) and is associated with a "proliferative" CMML phenotype and poor outcomes. 4, 16 Unlike in patients with myelofibrosis, where the salutatory effects and prognostic impact of splenectomy have been well defined, the role of splenectomy in patients with CMML is less lucid. In this largest-todate study, we present the indications, perioperative morbidity and mortality rates and outcomes in 39 patients with CMML. In our study, CMML patients that underwent splenectomy had a median age of 66 years and were younger than those that did not undergo splenectomy, potentially reflecting a selection bias, in which younger and fitter patients were selected for surgery, in contrast to the elderly and those with comorbidities. In addition, the higher presplenectomy AMC values in this group could also reflect aggressive disease biology and the fact that they were more likely to be symptomatic from proliferative features, including splenomegaly, once again resulting in a selection bias. 12 Fairly similar to patients with myelofibrosis, the perioperative morbidity and mortality rates in CMML patients undergoing splenectomy were 43% and 13%, respectively (31% and 9% in myelofibrosis). 5 Perioperative complications, once again in comparison to reported rates in myelofibrosis included infections/sepsis in 6 (20% vs 15%), intraabdominal bleeding in 4 (13% vs 9%), VTE in 3 (10% vs 1.3%), and acute lung injury in 2 (7% vs 0%) patients, respectively.
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The median post-splenectomy survival was 25 months (27 months in myelofibrosis) and there was no difference in OS and LFS between CMML patients that underwent splenectomy, vs those that did not.
The common indications for splenectomy in CMML were refractory thrombocytopenia 36%, progressive spleen related symptoms 33%, splenic rupture 21%, AIHA 8% and planned HCT 3%. In addition, 8 (20.5%) patients had concomitant anemia, with three being RBC transfusion dependant at the time of splenectomy. Durable remissions in spleen related symptoms, refractory thrombocytopenia, complications from splenic rupture, and refractory anemia were achieved in 85%, 50%, 62%, and 21% of patients, respectively. In contrast, in myelofibrosis, indications for splenectomy included RBC transfusion dependant anemia 45%, symptomatic splenomegaly 39%, and portal hypertension related sequela 11%; while splenectomy was performed for refractory thrombocytopenia in 5% of patients with no durable platelet responses. 5 There were no cases of splenic rupture reported in the myelofibrosis cohort and immune mediated cytopenias were uncommon. The FIGURE 2 Survival analysis in 555 patients with chronic myelomonocytic leukemia (CMML), stratified by as to whether or not they underwent a splenectomy, A, overall survival analysis of 555 CMML patients stratified by as to whether or not they underwent a splenectomy. B, Leukemia free survival analysis of 555 CMML patients stratified by as to whether or not they underwent a splenectomy [Color figure can be viewed at wileyonlinelibrary.com] prevalence rates of autoimmune diseases in patients with myeloid neoplasms ranges from 10% to 30%, [17] [18] [19] [20] [21] [22] with a higher prevalence in patients with CMML (~20-30%). [23] [24] [25] [26] In a large study of 377 CMML patients, autoimmune diseases were documented in 77 (20%), with 5 patients being diagnosed with ITP and one patient with AIHA. 25 In a large cohort of ITP patients (n = 565), CMML related ITP was identified in 8 (1.4%) patients. 27 This might explain the higher incidence of splenectomy in CMML patients for refractory thrombocytopenia and the higher durable platelet responses achieved. In addition, all CMML patients with thrombocytopenia who responded to splenectomy had abundant demonstrable foamy histiocytes in the spleen, a finding that has been demonstrated in a prior smaller series of 12 patients. 7 While this finding is nonspecific, the sheer abundance of these monocyte derived cells raises questions about clonal infiltration and altered immune surveillance. 26 These foamy histiocytes were not detectable in the BM specimens of affected patients and while they remain an attractive predictive marker for possible platelet response after splenectomy, these findings needed to be validated in a larger study. The impact of gene mutations, especially RUNX1 on platelet responses have been previously described, however, due to small numbers we
were not able to assess these correlations. 28 Response to splenectomy for AIHA in CMML patients was less robust.
The detection of CD123 (interleukin-3 receptor alpha) positive plasmacytoid dendritic cells in three spleen specimens correlates with the fact that these cells have been shown to be part of the CMML clone and could potentially alter immune responses and outcomes. [29] [30] [31] This finding also bears importance in lieu of the fact that SL-401 (Tagraxofusp), an antibody conjugate targeting CD123, is currently undergoing phase II trials in CMML, with preliminary data demonstrating a 71% spleen response rate and a 17% BM complete remission rate. 32 Splenic rupture was encountered in 8 (21%) patients, with 6 (75%) of these being spontaneous. In one patient with spontaneous splenic rupture, concomitant administration of G-CSF was documented; once again highlighting the concern of using hematopoietic growth factors in patients with CMML. Early studies with the thrombopoietin analogue eltrombopag for thrombocytopenia in CMML have also shown an increased incidence of "proliferative" features like leukocytosis, monocytosis and circulating blasts, warranting close scrutiny. 33 All patients with splenic rupture presented with spleen related pain and intraabdominal hemorrhage and in these patients an emergent splenectomy was a lifesaving procedure. Similar to myelofibrosis, elective splenectomy was also very effective in alleviating spleen related mechanical and constitutional symptoms (85% vs 67%). Unlike in myelofibrosis, none of the CMML patients developed extreme thrombocytosis after splenectomy (0% vs 22%), whereas the incidence of post-splenectomy compensatory liver enlargement was similar (19% vs 16%). 5 The low rate of post-splenectomy extreme thrombocytosis is almost certainly due to the low frequency of MPNdriver mutations like JAK2V617F (~10%), MPL, and CALR (<1% each) in CMML. 12 Immunization coverage perioperatively for encapsulated organisms such as streptococcus pneumoniae, neisseria meningitidis, and haemophilus influenza B was acceptable at 100%, 81%, and 63%, respectively; with no documented cases of pneumococcal or neisserial infections at last follow up. No patients received postoperative prophylaxis with penicillin. Three (10%) patients had histopathological evidence for additional malignancies on pathological review of spleen specimens; two of which were incidentally detected (anaplastic large cell lymphoma and mantle cell lymphoma), highlighting the importance of a detailed history of prior exposure to chemotherapy and/or ionizing radiation, as these agents can predispose towards the development of therapy related CMML, often associated with poor outcomes. 34, 35 One patient had aberrant mast cells detected in the spleen specimen, but did not meet WHO criteria for systemic mastocytosis (SM). SM-CMML is a well-defined entity, with a preponderance of KIT and CBL mutation in comparison to CMML, with additional morbidity from the mast cell clone, with similar survival outcomes. 15 Postsplenectomy mortality was seen in 5 patients and was secondary to acute lung injury 40%, MODS 40% and hemorrhagic shock 20%.
In conclusion, we demonstrate the effectiveness of splenectomy in CMML patients with regards to being lifesaving in the context of splenic rupture and being palliative in the setting of spleen related symptoms (mechanical and constitutional) and refractory thrombocytopenia (especially if suspected to be immune mediated).
The true prevalence of immune mediated cytopenias and the clonal origins and pathophysiological role of foamy histiocytes in the spleen of CMML patients, needs further elucidation.
